

## Differences in self-reported prevalence and management of cardiovascular risk factors in Switzerland, 2007

<sup>1</sup>Estoppey D., <sup>1</sup>Marques-Vidal P., <sup>1</sup>Paccaud F., <sup>1</sup>Bochud M.

*IUMSP CHUV<sup>1</sup>*

**Purpose:** To assess the prevalence of four self-reported cardiovascular risk factors (CV RFs: smoking, hypertension, dyslipidaemia and diabetes) and their reported management in seven Swiss regions (Léman, Mittelland, Zurich, North-West Switzerland, Oriental Switzerland, Central Switzerland and Tessin).

**Methods:** National health interview survey conducted in 2007 in a representative sample of the Swiss population (17,879 subjects). Age-adjusted data on prevalence of self-reported CV RFs, treatment among participants reporting a RF, control of RFs among treated participants and CV RF screening in the last 12 months levels were computed after weighting.

**Results:** The prevalence of hypertension was highest in North-West Switzerland (27.3%) and lowest in Central Switzerland (21.0%,  $p < 0.001$ ). Antihypertensive treatment was highest in Léman region (62.7%) and lowest in Oriental Switzerland (55.2%,  $p < 0.001$ ). Screening was higher in Tessin (89.3%) and lowest in Léman region (81.8%,  $p < 0.001$ ). Prevalence of dyslipidaemia was highest in Tessin and Léman region (20.7% and 20.1%, respectively) and lowest in Oriental Switzerland (14.5%,  $p < 0.001$ ). Lipid-lowering treatment was highest in Tessin and Léman region (44.3% each) and lowest in Central Switzerland (30.7%,  $p < 0.001$ ). Dyslipidaemia screening was highest in Tessin (76.6%) and lowest in Central Switzerland (58.6%,  $p < 0.001$ ). Prevalence of diabetes was highest in North-West Switzerland (5.4%) and lowest in Central Switzerland (3.3%,  $p < 0.05$ ). Diabetes screening was highest in Tessin (78.1%) and lowest in Oriental Switzerland (64.0%,  $p < 0.001$ ). Conversely, no between-region differences were found for hypertension or dyslipidaemia control (see table).

**Conclusion:** there are significant differences between the Swiss regions in self-reported prevalence and management of CV RFs. Screening is better in Tessin than in the other regions.

Faculty of Biology and Medicine

# CHUV Research Day

January 28, 2010

César Roux Auditorium

## Immunology and Cancer

*Unil*

UNIL | Université de Lausanne



# Contents

Message of the Vice-Dean for Research of the Faculty of Biology and Medicine .....	1
Programme .....	3
<b>Abstracts</b>	
EHU Human Environment .....	5
ENA Natural Environment.....	10
GEN Genes and Environment .....	12
IMI Immunity and Infectiology .....	28
MCV Metabolism and Cardiovascular .....	80
NEU Neurosciences .....	111
ODE Oncology and Development.....	131
THE Therapeutic Procedures .....	162
Authors' Index.....	176

Cover: Yannick Kremp, Department of Cell Biology and Morphology – UNIL

Photo: Flow cytometry study of expression of the B and T Lymphocyte Attenuator (BTLA) on human tumor specific CD8 T lymphocytes and effect of cancer vaccination provided by L. Derré et al., Division of Clinical Oncolmmunology, Ludwig Institute for Cancer Research, Lausanne branch, UNIL